ArticleNPJ precision oncology2024

Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab.

Douglas I Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.